Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis

References

• Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F, et al. Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients’ population and review of the literature. Autoimm Rev. 2014;13:1026–34.
   PubMed Web of Science ®Google Scholar
• Carpentier Ph, Maricq Hr. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am. 1990;16:75–91.
   PubMed Web of Science ®Google Scholar
• Barsotti S, Stagnaro C, Della Rossa A. Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol. 2015;33:S3–14.
   PubMed Web of Science ®Google Scholar
• Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am. 2008;34:89–114.
   PubMed Web of Science ®Google Scholar
• Chora I, Guiducci S, Manetti M, Romano E, Mazzotta C, Bellando-Randone S, et al. Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. Autoimmun Rev. 2015;14:314–22.
   PubMed Web of Science ®Google Scholar
• Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000953.
   PubMedGoogle Scholar
• Wall LB, Stern PJ. Nonoperative treatment of digital ischemia in systemic sclerosis. J Hand Surg Am. 2012;37:1907–9.
   PubMed Web of Science ®Google Scholar
• D’Amelio P, Cristofaro MA, D’Amico L, Veneziano L, Roato I, Sassi F, et al. Iloprost modulates the immune response in systemic sclerosis. BMC Immunol. 2010;11:62.
   PubMed Web of Science ®Google Scholar
• Shah P, Murray AK, Moore TL, Herrick AL. Effects of iloprost on microvascular structure assessed by nailfold videocapillaroscopy: a pilot study. J Rheumatol. 2011;38:2079–80.
   PubMed Web of Science ®Google Scholar
• Korn JH, Mayes M, Matucci-Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–93.
   PubMed Web of Science ®Google Scholar
• Seibold JR, Matucci Cerinic M, Denton CP, Furst DE, Mayes MD, Kramer F, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis. 2006;65(suppl ii):90.
   Google Scholar
• Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum. 1991;34:978–83.
   PubMed Web of Science ®Google Scholar
• Balbir-Gurman A, Braun-Moscovici Y. Scleroderma – new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol. 2012;26:13–24.
   PubMed Web of Science ®Google Scholar
• Agard C, Carpentier PH, Mouthon L, Clerson P, Gressin V, Bérezné A, et al. Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval. Scand J Rheumatol. 2014;43:398–402.
   PubMed Web of Science ®Google Scholar
• Lee P, Leung FY, Alderdice C, Armstrong SK. Nailfold capillary microscopy in the connective tissue diseases: a semiquantitative assessment. J Rheumatol. 1983;10:930–8.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol. 2000;27:155–60.
   PubMed Web of Science ®Google Scholar
• Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis. 2008;67:885–7.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Colaci M, D’amico R, Malagoli V, Giuggioli D, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in Systemic Sclerosis Patients. Arthritis Rheum. 2009;61:688–94.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Vukatana G, Moscatelli S, Riato L, Bocci M, et al. Predictive role of capillaroscopy skin ulcer risk index in systemic sclerosis: a multicentre validation study. Ann Rheum Dis. 2012;71:67–70.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Manfredi A, Lo Monaco A, Praino E, Riccieri V, Grattagliano V, et al. Capillaroscopic skin Ulcers Risk Index (CSURI) calculated with different videocapillaroscopy devices: how its predictive values change. Clin Exp Rheumatol. 2013;31:S115–17.
   PubMed Web of Science ®Google Scholar
• Manfredi A, Sebastiani M, Carraro V, Iudici M, Bocci M, Vukatana G, et al. Prediction risk chart for scleroderma digital ulcers: a composite predictive model based on capillaroscopic, demographic and clinico-serological parameters. Clin Hemoreol Microcirculat. 2015;59:133–43.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–55.
   PubMed Web of Science ®Google Scholar
• Grassi W, De Angelis R. Capillaroscopy: questions and answers. Clin Rheumatol. 2007;26:2009–16.
   PubMed Web of Science ®Google Scholar
• Maricq HR, Spencer-Green G, Leroy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med. 1976;61:862–70.
   PubMed Web of Science ®Google Scholar
• Ingegnoli F, Ardoino I, Boracchi P, Cutolo M; EUSTAR co-authors. Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. Microvasc Res. 2013;89:122–8.
   PubMed Web of Science ®Google Scholar
• Andrade LE, Gabriel Júnior A, Assad RL, Ferrari AJ, Atra E. Panoramic nailfold capillaroscopy: a new reading method and normal range. Semin Arthritis Rheum. 1990;20:21–31.
   PubMed Web of Science ®Google Scholar
• Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991.
   Google Scholar
• Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TAJr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199–206.
   PubMed Web of Science ®Google Scholar
• Wigley FM, Seibold JR, Wise RA, Mccloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992;19:1407–14.
   PubMed Web of Science ®Google Scholar
• Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F, et al. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol. 2012;31:1723–5.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Zampogna G, Vremis L, Smith V, Pizzorni C, Sulli A. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol. 2013;40:40–5.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Ruaro B, Pizzorni C, Ravera F, Smith V, Zampogna G, et al. Longterm treatment with endothelin receptor antagonist bosentan and iloprost improves fingertip blood perfusion in systemic sclerosis. J Rheumatol. 2014;41:881–6.
   PubMed Web of Science ®Google Scholar
• Romano E, Bellando-Randone S, Manetti M, Bruni C, Lepri G, Matucci-Cerinic M, et al. Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. Clin Exp Rheumatol. 2015;33:S148–52.
   PubMed Web of Science ®Google Scholar
• Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31(2):407–15.
   PubMed Web of Science ®Google Scholar
• Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary hypertension: does selectivity matter? Eur Heart J. 2008;29:1936–48.
   PubMed Web of Science ®Google Scholar
• Price LC, Howard LS. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs. 2008;8(3):171–85.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Bosentan – a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs. 2009;69(14):2005–24.
   PubMed Web of Science ®Google Scholar
• Fishman AP. Pulmonary hypertension – beyond vasodilator therapy. N Engl J Med. 1998;338:321–2.
   PubMed Web of Science ®Google Scholar
• Riccieri V, Vasile M, Iannace N, Stefanantoni K, Sciarra I, Vizza CD, et al. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. Rheumatology. 2013;52:1525–8.
   PubMed Web of Science ®Google Scholar